Drugs / CAR-CD19 T cells
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02933775 | Oct 2016 → Apr 2018 | B-cell acute lymphoblastic leukemia | RenJi Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT03016377 | Mar 2012 → Sep 2025 overdue | acute lymphoblastic leukemia, immunoproliferative disorder | UNC Lineberger Comprehensive Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03994913 | Aug 2019 → Jan 2021 | B-cell non-Hodgkin lymphoma | CARsgen Therapeutics Co., Ltd. | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT03594162 | — | acute lymphoblastic leukemia, immunoproliferative disorder | UNC Lineberger Comprehensive Cancer Center | No longer available | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAR-CD19 T cells | “This study is a single-arm, open label, phase I/II clinical trial to evaluate the safety, efficacy and cellular kinetics of CT032 CAR-CD19 T cells in patients with R/R B-NHL.” NCT03994913 ↗ |
| Known as | iC9-CAR19 cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03016377 ↗ |
| Action | Deplete | “These CD19 chimeric (combination) receptor-activated T cells kill some of the tumor” NCT03016377 ↗ |
| Modality | Cell therapy | “Autologous T Cells with a CD19-redirected Chimeric Antigen Receptor.” NCT02933775 ↗ |
| Route | Intravenous | “Route of administration: Intravenous injection.” NCT02933775 ↗ |
| Target | CD19 | “anti-CD19 lentiviral vector” NCT02933775 ↗ |